-

Foundation Medicine Appoints Dan Malarek as Chief Executive Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc., today announced the appointment of Roche executive, Dan Malarek, as Chief Executive Officer (CEO). Malarek succeeds Brian Alexander, M.D., who will take on a senior leadership role in Roche’s Pharma Research and Development based in Boston.

Malarek has more than 15 years of experience in the diagnostics industry. Since January 2021, he has served as Global Head of Marketing & Customer Insights at Roche Diagnostics. Prior to this, he held multiple roles within Roche Diagnostics across various geographies with both global and local responsibilities.

“Dan’s depth of experience in product development combined with his passion for serving customers makes him the perfect leader to take Foundation Medicine forward and accelerate the company’s mission of transforming cancer care,” said Matt Sause, CEO Roche Diagnostics. “We also want to thank Brian for his leadership and many contributions and wish him the best in his new role.”

Commenting on his appointment, Dan Malarek said, “I am honored to serve as Foundation Medicine’s new CEO. Foundation Medicine is an extraordinary company that plays a critical role in empowering personalized cancer treatment solutions.”

Foundation Medicine is an independent affiliate of the Roche Group.

About Foundation Medicine: Your Essential Partner in Cancer Care
Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. Every day, we are driven to help our partners find answers and take action, enabling more people around the world to benefit from precision cancer care. For more information, please visit us on www.FoundationMedicine.com and follow us on Twitter and LinkedIn.

Contacts

Media:
Foundation Medicine:
Holly Campbell, 480-213-8368
newsroom@foundationmedicine.com

Foundation Medicine


Release Versions

Contacts

Media:
Foundation Medicine:
Holly Campbell, 480-213-8368
newsroom@foundationmedicine.com

Social Media Profiles
More News From Foundation Medicine

U.S. Food and Drug Administration Approves FoundationOne®CDx as a Companion Diagnostic for Itovebi™ (inavolisib) to Identify Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx to be used as a companion diagnostic for Itovebi™ (inavolisib) in combination with palbociclib (Ibrance®) and fulvestrant. Itovebi is a therapy developed by Genentech, a member of the Roche group, which is approved for the treatment of adult patients with endocrine-resistant,...

Foundation Medicine and SWOG Clinical Trials Partnerships Announce Strategic Collaboration to Advance Biomarker-Driven Research and Clinical Trials

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a global, patient-focused precision medicine company, and SWOG Clinical Trials Partnerships (SWOG CTP) today announced a strategic partnership to advance biomarker-driven research and clinical trials, marking the first collaboration of this nature with a diagnostic company. This partnership builds upon Foundation Medicine’s decade-long collaboration with SWOG Cancer Research Network through the Lung Cancer Master Protocol (Lung-MAP) trial, a m...

US FDA Approves FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for TALZENNA® (talazoparib) in Combination with XTANDI® (enzalutamide) to Identify Patients with HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced that it has received approvals from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx and FoundationOne®Liquid CDx to be used as companion diagnostics for Pfizer’s TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide) to identify patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRP...
Back to Newsroom